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OBJECTIVES This study sought to investigate the effect of beraprost sodium (BPS), an orally active
prostacyclin analogue, on the survival of outpatients with primary pulmonary hypertension
(PPH).
BACKGROUND Continuous intravenous administration of epoprostenol (prostacyclin) has been shown to
improve survival in PPH. However, the effect of oral BPS on survival in PPH remains
unknown.
METHODS Fifty-eight consecutive patients with PPH who could be discharged after the first diagnostic
catheterization for PPH were retrospectively divided into two groups: patients treated with
BPS (BPS group, n 5 24) and those without BPS (conventional group, n 5 34). The baseline
demographic and hemodynamic data did not significantly differ between the two.
RESULTS Twenty-seven patients died of cardiopulmonary causes in the conventional group during a
mean follow-up period of 44 6 45 months. In contrast, only 4 patients died of cardiopul-
monary causes in the BPS group during a mean follow-up period of 30 6 20 months. In a
subsample (n 5 15) of patients in the BPS group, mean pulmonary arterial pressure and total
pulmonary resistance significantly decreased, respectively, by 13% and 25% during a mean
follow-up period of 53 days. Among the variables previously known to be associated with the
mortality in PPH, the absence of BPS therapy and the reduced cardiac output were
independently related to the mortality by a multivariate Cox proportional hazards regression
analysis (both p , 0.05). The Kaplan-Meier survival curves demonstrated that the one-, two-
and three-year survival rates for the BPS group were 96%, 86% and 76%, respectively, as
compared with 77%, 47% and 44%, respectively, in the conventional group (log-rank test, p ,
0.05).
CONCLUSIONS The oral administration of BPS may have beneficial effects on the survival of outpatients with
PPH as compared with conventional therapy alone. (J Am Coll Cardiol 1999;34:1188–92)
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Primary pulmonary hypertension (PPH) is a rare, but
life-threatening disease characterized by progressive pulmo-
nary hypertension, ultimately producing right ventricular
failure and death (1). Although a variety of vasodilators have
been proposed as a potential therapy for PPH over the past
30 years (2-6), there have been conflicting results with these
vasodilators, and some patients ultimately require heart-
lung or lung transplantation (7–9). Recently, continuous
intravenous infusion of epoprostenol (prostacyclin) has been
introduced as a treatment for advanced PPH (10,11).
Long-term therapy with epoprostenol markedly lowered
pulmonary vascular resistance in patients with PPH (12,13).
A prospective, randomized study has shown sustained
clinical benefits of epoprostenol and improved long-term
survival in patients who received this agent (14). This
treatment, however, requires a continuous intravenous in-
fusion device, hence being more uncomfortable and expen-
sive than taking oral medications.
Beraprost sodium (BPS) is a newly developed prostacy-
clin analogue with a stable structure because of its cyclo-
pentabenzofuranyl skeleton (15). Unlike epoprostenol, BPS
permits oral ingestion because of its long-lasting activities
(16). Like epoprostenol, BPS produces strong vasodilation
and inhibition of platelet aggregation (17). Recently, we
have shown that long-term therapy with BPS reduces
pulmonary vascular resistance in patients with PPH (18).
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However, whether oral BPS improves long-term survival in
PPH remains unknown. Thus, in this study, we sought to
investigate the effect of BPS on the survival of outpatients
who could be discharged after the first diagnostic catheter-
ization for PPH.
METHODS
Study subjects. We enrolled 58 consecutive patients who
could be discharged after the first diagnostic catheterization
for PPH between June 1981 and August 1997. PPH was
defined as pulmonary hypertension unexplained by any
secondary cause, based on the criteria of National Institutes
of Health registry on PPH (1). The 24 patients diagnosed
between January 1993 and August 1997 were treated with
BPS in addition to conventional therapy, serving as a BPS
group. The other 34 patients diagnosed before December
1992 were treated with conventional therapy alone: calcium
antagonists, nitrates, digitalis and diuretics, serving as a
conventional group. Calcium antagonists were used in
patients who showed a more than 20% decrease in total
pulmonary resistance by short-term oral administration of
nifedipine (20 mg). This study was designed to maintain
BPS therapy at the highest dose tolerated. Oral administra-
tion of BPS was begun at a rate of 60 mg/day and was
increased by increments of 60 mg/day over one to two weeks
until the highest dose tolerated (range 5 60 to 180 mg/day).
The daily dose was split into three or four times. Within one
week of the administration of BPS, several side effects
occurred in 10 patients (42%): flushing in 4 patients;
headache in 2; flushing and headache in 2; arthralgia in 1;
diarrhea and nausea in 1. When the adverse effects of BPS
occurred, either the dose of BPS was reduced or the same
daily dose was given by splitting. All patients in the BPS
group eventually tolerated at least 60 mg/day of BPS.
Additional therapy for PPH and right ventricular failure,
such as anticoagulation, digitalis and diuretics, was pre-
scribed by attending physicians ad libitum.
Hemodynamic studies. Baseline hemodynamic variables
including mean pulmonary arterial pressure, mean right
atrial pressure, pulmonary capillary wedge pressure and
mean systemic arterial pressure were measured at end
expiration in all patients by right heart catheterization.
Cardiac output was measured by Fick’s method (19). Total
pulmonary resistance was calculated by dividing mean pul-
monary arterial pressure by cardiac output. Hemodynamic
measurements were repeated in a subsample (n 5 15) of
study patients after a mean follow-up period of 53 days in
order to assess the long-term hemodynamic effects of BPS.
Survival estimates. Survival was estimated from the date of
initial diagnosis to November 30, 1998, or the death of the
patient. Patients who received the continuous intravenous
infusion of epoprostenol or transplantation and those who
died of noncardiac causes were judged at that time point.
Four patients in the conventional group to whom BPS was
later prescribed by attending physicians were also judged at
that time point.
Statistical analysis. All data were expressed as mean val-
ues 6 SD. Comparisons between two groups were made by
the Fisher exact test or the unpaired Student t test. Hemo-
dynamic effects of BPS therapy were analyzed with the
paired Student t test. To determine whether BPS therapy
had independent prognostic significance, the following
seven variables were entered into a multivariate Cox pro-
portional hazards regression analysis: mean pulmonary ar-
terial pressure, cardiac output, mean right atrial pressure,
arterial oxygen pressure, mixed venous oxygen saturation,
absence of anticoagulation and absence of BPS therapy.
Survival curves according to the presence or absence of BPS
therapy were derived using the Kaplan-Meier method and
compared using log-rank tests. A p value ,0.05 was
considered statistically significant.
RESULTS
Demographic, hemodynamic and pulmonary function data
at baseline did not significantly differ between the BPS
group and the conventional group (Table 1). There was no
difference in the frequency of using anticoagulant agents,
nitrates, diuretics and home oxygen therapy between the
groups, except that digitalis and calcium antagonists were
more frequently used in the conventional group than in the
BPS group.
Of the 34 patients in the conventional group, 27 patients
died of cardiopulmonary causes, 1 died of a traffic accident,
1 had lung transplantation and 1 patient received continu-
ous intravenous infusion of epoprostenol during a mean
follow-up period of 44 6 45 months. In contrast, of the 24
patients in the BPS group, only 4 patients died of cardio-
pulmonary causes and 4 patients received continuous intra-
venous infusion of epoprostenol during a mean follow-up
period of 30 6 20 months.
Long-term therapy with BPS significantly lowered mean
pulmonary arterial pressure and total pulmonary resistance
by 13% and 25%, respectively (Fig. 1). Cardiac output
significantly increased by 17%. There was a slight reduction
in mean systemic blood pressure (84 6 9 to 78 6
11 mm Hg). New York Heart Association functional class
improved in 16 patients (67%), worsened in 2 (8%) and was
unchanged in 6 (25%).
Among the variables previously known to be associated with
the mortality in PPH, i.e., mean pulmonary arterial pressure,
cardiac output, mean right atrial pressure, arterial oxygen
pressure, mixed venous oxygen saturation and anticoagulation
therapy (20–22), the absence of BPS therapy and the reduced
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cardiac output were independently related to the mortality
(Table 2). The Kaplan-Meier survival curves demonstrated
that the BPS group had a significantly higher survival rate than
the conventional group (log-rank test, p ,0.05; Fig. 2). The
one-, two- and three-year survival rates for the BPS group were
96%, 86% and 76%, respectively, as compared with 77%, 47%
and 44%, respectively, in the conventional group.
DISCUSSION
The mean survival of patients with PPH has been reported
to be two to three years after the diagnosis (22). In the
present study, however, 80% of outpatients treated with oral
BPS survived even after a mean follow-up period of 2.5
years. The absence of BPS therapy and the reduced cardiac
output were independently related to mortality by a multi-
variate Cox proportional hazards regression analysis. The
Kaplan-Meier survival curves demonstrated that the BPS
group had a significantly higher survival rate than the
conventional group. These results suggest that the oral
administration of BPS may have beneficial effects on the
survival of outpatients with PPH as compared with conven-
tional therapy alone.
Conventional medical approaches for patients with PPH
include the treatment with anticoagulants (21) and oral
vasodilators (2-6). Rich et al. confirmed the beneficial effects
Table 1. Baseline Characteristics in Patients Treated With
Conventional Therapy and Those With Beraprost Sodium
Variables
Conventional
Group
(n 5 34)
BPS
Group
(n 5 24) p
Demographics
Age (years) 33 6 13 39 6 18 NS
Gender (male/female) 11/23 9/15 NS
NYHA functional class
III (n) 31 22 NS
IV (n) 3 2 NS
Hemodynamics
Heart rate, beats/min 84 6 12 78 6 16 NS
mSAP (mm Hg) 81 6 9 82 6 7 NS
mPAP (mm Hg) 57 6 16 56 6 15 NS
CO (liters/min) 3.5 6 1.6 3.6 6 1.1 NS
TPR (Wood units) 19 6 8 17 6 7 NS
RAP (mm Hg) 6 6 4 7 6 3 NS
PCWP (mm Hg) 7 6 3 8 6 3 NS
Pulmonary function
PaO2 (mm Hg) 73 6 11 72 6 12 NS
PaCO2 (mm Hg) 31 6 4 34 6 4 NS
SvO2 (%) 62 6 9 62 6 8 NS
FVC (% predicted) 89 6 15 88 6 16 NS
FEV1 (% predicted) 79 6 10 81 6 10 NS
Medication use at discharge
Anticoagulant agents (%) 76 63 NS
Calcium antagonists (%) 38 12 ,0.05
Nitrates (%) 18 12 NS
Digitalis (%) 70 25 ,0.01
Diuretics (%) 70 58 NS
Home oxygen therapy (%) 59 58 NS
BPS 5 beraprost sodium; CO 5 cardiac output; FEV1 5 forced expiratory volume in 1 s;
FVC 5 forced vital capacity; mPAP 5 mean pulmonary arterial pressure; mSAP 5 mean
systemic arterial pressure; NS 5 not significant; NYHA 5 New York Heart Association
functional class; PaCO2 5 arterial carbon dioxide pressure; PaO2 5 arterial oxygen
pressure; PCWP 5 pulmonary capillary wedge pressure; RAP 5 mean right atrial
pressure; SvO2 5 mixed venous oxygen saturation; TPR 5 total pulmonary resistance.
Figure 1. Long-term effects of beraprost sodium on: (A) mean pulmonary arterial pressure (mPAP), (B) cardiac output (CO) and (C) total
pulmonary resistance (TPR).
Table 2. Multivariate Analysis of Variables Associated With
Mortality in Primary Pulmonary Hypertension
Variable
Risk
Ratio
Estimate 95% CI p
mPAP 0.999 0.969–1.029 0.9325
CO 0.627 0.395–0.996 0.0481
RAP 0.907 0.800–1.029 0.1289
PaO2 0.998 0.964–1.033 0.9077
SvO2 0.967 0.902–1.037 0.3508
Absence of
anticoagulation
1.202 0.465–3.101 0.7043
Absence of BPS therapy 4.649 1.487–14.534 0.0082
BPS 5 beraprost sodium; CI 5 confidence interval; CO 5 cardiac output; mPAP 5
mean pulmonary artery pressure; PaO2 5 arterial oxygen pressure; RAP 5 mean right
atrial pressure; SvO2 5 mixed venous oxygen saturation.
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of anticoagulant agents and calcium-channel blockers on
survival in PPH (6). Nevertheless, there are some patients
refractory to those medical treatments, ultimately requiring
heart-lung or lung transplantation (7–9). Recently, contin-
uous intravenous administration of epoprostenol (prostacy-
clin) has significantly improved survival of patients with
PPH as compared with conventional therapy alone (14,23).
More recently, long-term therapy with epoprostenol has
been shown to markedly lower pulmonary vascular resis-
tance beyond the level of acute vasodilator response to
adenosine (12). Based on these studies, the intravenous
infusion of prostacyclin has been established as treatment of
PPH. However, epoprostenol is quickly metabolized and
hence requires continuous intravenous administration.
Quality of life and cost effectiveness still remain as impor-
tant issues to be resolved. Thus, BPS, a prostacyclin
analogue, was first developed in Japan (18).
In contrast to epoprostenol, BPS can be orally ingested
because of its long-lasting activities (16). In humans, oral
administration of BPS has acutely reduced pulmonary
hypertension both in responders and in nonresponders to
nitric oxide (25). In this study, long-term therapy with BPS
significantly lowered mean pulmonary arterial pressure and
total pulmonary resistance, although the hemodynamic
responses to BPS were relatively small compared with
intravenous epoprostenol therapy (10–12). Antiplatelet ac-
tion as well as vasodilator activity of BPS may contribute to
the long-term beneficial effects (17). Oral BPS has inhibited
the development of monocrotaline-induced pulmonary hy-
pertension and has reduced medial thickness of the pulmo-
nary artery in rats (24). It is interesting to speculate that
long-term treatment with BPS may inhibit vascular remod-
eling and vascular growth in patients with PPH. Further
investigations are necessary regarding the mechanisms re-
sponsible for the improvement in the survival by oral BPS.
The mortality of patients with PPH have been shown to
be associated with those variables of right ventricular func-
tion, that is, mean pulmonary arterial pressure, cardiac
output and mean right atrial pressure (20,22). Mixed venous
oxygen saturation, arterial oxygen pressure and anticoagu-
lation therapy have also been related to the mortality
(20,21). In this study, the absence of BPS was indepen-
dently related to the mortality among the variables previ-
ously known to be associated with the mortality in PPH.
Furthermore, the Kaplan-Meier survival curves demon-
strated that the one-, two- and three-year survival rates for
the BPS group were 96%, 86% and 76%, respectively, as
compared with 77%, 47% and 44%, respectively, in the
conventional group. Although this study population com-
prised outpatients with PPH who could be discharged after
the first diagnostic catheterization, excluding patients with
the most severe forms of PPH, the oral administration of
BPS may have beneficial effects on the survival of the
patients with milder forms of PPH. Given the potential
risks and high medical costs of the invasive method, orally
active BPS may be worth trying in such patients before the
intravenous infusion therapy is considered.
Study limitations. The patients who could not tolerate any
vasodilator therapy due to the hypotension resulting from
uncompensated right heart failure and died during the
hospitalization were not enrolled in this study. This study
may therefore include milder forms of PPH than earlier
studies (20,22,23). Thus, effects of oral BPS in most severe
forms of PPH remains unknown.
This study was retrospective, and the time point for the
enrollment and the follow-up period differed between the
BPS group and the conventional group, which might bias
the results of this study. In addition, the subsequent therapy,
which included calcium channel antagonists and digitalis,
was not controlled in this study. These drugs might have an
effect on mortality in PPH. Although other demographic,
hemodynamic and pulmonary function data at baseline did
not significantly differ between the groups, a prospective,
randomized and multicenter trial should be planned.
The mean follow-up period of the conventional group in
Figure 2. Kaplan-Meier survival curves showing that outpatients treated with beraprost sodium (BPS) have a significantly higher survival
rate than those treated with conventional therapy (log-rank test, p , 0.001).
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this study exceeded the average survival of PPH previously
reported by earlier studies (21,22). Because our study
included only outpatients with PPH, who could be dis-
charged after the first diagnostic catheterization, the average
survival in our study may be longer than that in the whole
patients with PPH.
Long-term hemodynamic effects of BPS were examined
only in 15 patients who accepted the repeated right heart
catheterization. However, there was no significant differ-
ence in baseline total pulmonary resistance (18 6 6 vs. 17 6
7 Wood units) or clinical outcome (death number, 4 vs. 1)
between the 15 patients and the remaining 9 patients.
Four patients in the BPS group and one patient in the
conventional group developed heart failure, eventually re-
ceiving continuous intravenous infusion of epoprostenol,
and they are still alive. The results would not have been
different even if these five had died of cardiopulmonary
causes. Further studies are necessary to determine the
indications for the intravenous infusion of epoprostenol and
for the oral BPS.
Conclusions. Although retrospective, this study suggests
that the oral administration of BPS may have beneficial
effects on the survival of outpatients with PPH as compared
with conventional therapy alone.
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